Jennifer L. Garst, MD

Related Content

Services

• Esophageal Cancer
• Lung Cancer
• Palliative Care

Department / Division:
Medicine / Medical Oncology

Address:
DUMC 3198
Durham, NC 27710

Appointment Telephone:
(919) 668-6688

Office Telephone:
(919) 668-6688

Fax Telephone:
(919) 681-LUNG

• M.D., Medical College of Georgia, 1990

• Internal Medicine, University of Texas Southwestern, Parkland Memorial Hospital, 1990-1993
• Hematology/Oncology, Duke University Medical Center, North Carolina, 1993-1996

Clinical Interests:
Lung cancer (non-small cell and small cell), lung cancer as a women's health issue, lung cancer clinical trials and clinical research, general hematology and medical oncology, supportive care for lung cancer patients, multimodality treatment approaches for lung cancer, lung cancer vaccine clinical trials, genomic approaches to managing lung cancer

Research Interests:
1. Non-small cell and small cell lung cancer - intervention, epidemiology and treatment.
2. Clinical trials of combined modality therapy, cancer drug development, and new treatment approaches and supportive care for lung cancer.  
3. Lung cancer as a women's health issue.
4. Supportive care for lung cancer patients including management of taste alteration, weight loss and declining performance status.
5.   Clinical research in the Duke Oncology Outreach (DOORS) & DOC affiliate setting.
6.   Standardization of management for common oncologic problems.

Clinical Research:

1. Principal Investigator:
TOP 96-02, "A Phase I/II Dose Escalation Study of Concurrent Navelbine and Radiation Inoperable Stage III"
TOP 96-03, "A Phase I/II Study of Weekly Docetaxel and Vinorelbine in Advanced and Relapsed Non-Small Cell Lung Carcinoma"
TOP 97-01, "A Phase I/II Study: Sequential Topotecan and Carboplatin/VP-16 for the Treatment of Small Cell Lung Cancer"
TOP 98-01, "A Phase I/II Study:  Weekly CPT-11 with Vinorelbine in Advanced Non-Small Cell Lung Carcinoma"
TOP 98-02, "A Phase I/II Trial of Concurrent Carboplatin and Vinorelbine  Chemotherapy with Radiation Followed by Surgery in Patients with Non-Small Cell Lung Carcinoma"
TOP 99-01, "A Feasibility Trial of Filgrastim-SD/01 to Support Carboplatin/ Navelbine (SD/01-CaN) Chemotherapy for the Treatment of Thoracic Malignancies"
TOP 00-03, "Phase II Trial of Gemcitabine and Oxaliplatin in the Treatment of Non-Small Cell Lung Cancer (NSCLC)"
TOP 00-01, "A Pilot Study of the Relative Velocity of Serum Tumor Marker CYFRA 21-1 as an Indicator of Early Chemotherapeutic Response in Advanced Non-Small Cell Lung Cancer"
"Evaluation of Oral Antiemetic Regimens for Moderately-High to Highly Emetogenic Chemotherapy: Pilot Study of Oral Ondansetron in Acute Chemotherapy Inducted Emesis (CIE) and a Randomized Double Blind Comparison of Ondansetron versus Dexamethasone versus Procholorperazine in Delayed CIE"
2.  Co-Principal Investigator:
                       "A Phase I/II Study of Active Immunotherapy with Dexosomes Loaded with
                                   Mage3.A2 and Mage4.A2 Peptides in HLA A2+ Patients with Metastatic
                                   Non-Small Cell Lung Cancer Expressing Mage3 or Mage4 (AP Cells,
                                   Inc.)"
3D 97-01,  "A Phase I Dose Escalation Research Study of Radiotherapy Using Three-Dimensional Treatment Planning Following Neoadjuvant Chemotherapy for Stage IIB/III Non-Small Cell Lung Cancer"
                       "Phase IV Pharmacokinetic Study in Chemonaive Patients with Stage IIIB or IV
                        Non-Small Cell Lung Cancer (NSCLC) Receiving Gemcitabine and
                                    Cisplatin (Eli Lilly B9E-MC-JHQK)"
3.  Initiation, organization and development of the Multidisciplinary Thoracic Oncology clinic  
      with clinical research at DVAMC, 1996
4.  Development of four oncology clinical pathways at Duke University Medical Center, 1997
5.  Implementation of 3 clinical research trials at DOORS Asheboro site, Randolph Hospital,  
     1997

Representative Publications:
2. Anscher MA, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE, Garst J, Crawford J, Jirtle RL. Using Plasma Transforming Growth Factor b1 during Radiotherapy to Select Patients for Dose Escalation. J Clin Onc 19(17):3758-3765, 2001. (2001)

4. Crawford J, Garst J, Herndon JEII, Ringenberg SQ, Glenn L, Szatrowski TP, Jaffe HJ, Propert KJ, Green MR. A Phase I/II Study of Recombinant Human Gamma Interferon in Patients with Advanced Non-Small Cell Lung Cancer: A Cancer and Leukemia Group B Study. Manuscript in revision 2000. (2000)

1. Socinski MA, Marks LB, Garst J, Sibley GS, Blackstock W, Turrisi A, Herndon J, Zhou S, Anscher M, Crawford J, Shafman T, Roseman J. Carboplatin/Paclitaxel or Carbopaltin/ Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: A Preliminary Report of a Phase I Dose Escalation Trial from the Carolina Conformal Therapy Consortium. The Oncologist 6(Suppl 1):20-24, 2001. (2001)

Garst J, Crawford J, O'Rourke M, Herndon J, Traxler L, Blackwell S, Shoemaker D, Burman S, Hohneker J. Vinorelbine and Carboplatin for the Treatment of Advanced Non-Small Cell Lung Cancer: A Phase I/II Response, Toxicity and Survival Study. Submitted to Lung Cancer.

Garst J, Herndon J, Rosner G, Johnston E, Blackwell S, Campagna L, Crawford J. A Phase I Study: Weekly CPT-11 with Vinorelbine in Advanced Non-Small Cell Lung Carcinoma. In preparation.

Vokes EE, Leopold KA, Herndon JEII, Garst J, Cooper MR, Clamon GH, Epstein JM, Green MR. A Randomized Phase II Study of Gemcitabine or Paclitaxel or Vinorelbine with Cisplatin as Induction Chemotherapy (Ind CT) and Concomitant Chemotherapy (XRT) for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC). CALGB Study 9431. Submitted.